Abbott begins U.S. sales of SimpleScreen CRC, an FDA-approved blood test for average-risk colorectal cancer screening

Abbott has started commercial sales in the United States of SimpleScreen CRC, a blood‑based test cleared by the FDA for colorectal cancer screening in adults 45 years and older who are at average risk.

The test is developed and manufactured by Freenome and will be sold exclusively by Abbott, adding a blood‑based option to the company’s existing colorectal cancer screening portfolio, which already includes stool‑based products.

SimpleScreen CRC joins Abbott’s offerings after the company’s acquisition of Exact Sciences, giving clinicians both stool and blood screening choices for patients who prefer one method over the other.

Colorectal cancer remains the second leading cause of cancer death in the U.S., but early detection through screening can greatly improve outcomes. The launch targets the many adults who have never been screened, a group estimated at 28 million in 2025.